Two Biotech Stocks Plunge

WASHINGTON—Resignations of top officials at two biotechnology companies and predictions of lackluster earnings sent their stock prices tumbling last month. Applied Biosystems Inc. announced that Sam Eletr, the company's founder and chairman, was stepping down for personal reasons. It also said it expected third-quarter earnings to decline because of product delays and weak orders from Europe. Following that news, its stock dropped from $41.40 to $30 a share. The Foster City, Calif., firm,

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Applied Biosystems Inc. announced that Sam Eletr, the company's founder and chairman, was stepping down for personal reasons. It also said it expected third-quarter earnings to decline because of product delays and weak orders from Europe.

Following that news, its stock dropped from $41.40 to $30 a share. The Foster City, Calif., firm, founded in 1981, has become the leading manufacturer of instruments and chemicals used in DNA synthesis.

Meanwhile, Endotronics Inc. announced that founders Eugene Gruenberg and his son, Michael, will leave their jobs as top officers amid investigations by the Securities and Exchange Commission and the Minnesota Department of Commerce. The Minneapolis company also said that it expected "substantial losses" for fiscal 1987, and that it may run out of cash and credit by next month.

That news sent the company's stock price down $1.75 to close at $2.25 a share.

Endotronics stock had been trading in the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies